Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 4:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 1,809 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Type 1 Diabetes Clear all
Active, not recruiting Not applicable Interventional

iHERO Study: Insurance, Health and Economic Resources Online for Emerging Adults With Type 1 Diabetes

NCT06348160
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
iHERO Toolkit Resource
Behavioral
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 30 Years
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
4
States / cities
Los Angeles, California • Gainesville, Florida • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 27, 2026, 4:01 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Anti-Tac for Treatment of Leukemia

NCT00001941
View directory record Official record
Conditions
HTLV-I Infection, T Cell Leukemia
Interventions
daclizumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
10 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 20, 2012 · Synced Oct 27, 2026, 4:01 AM EDT
Completed Phase 2 Interventional

A Study Comparing the Pharmacodynamic Properties of Insulin VIAJECT™, Regular Human Insulin, and Insulin Lispro

NCT01000922
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Regular Human Insulin, Lispro, VIAject, VIAject 50%, VIAject/Insulin Glargine, Insulin Glargine/VIAject
Drug
Lead sponsor
Biodel
Industry
Eligibility
19 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2015 · Synced Oct 27, 2026, 4:01 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Novel Biomarker for Development of T2D

NCT02326129
View directory record Official record
Conditions
Diabetes Type II
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
12 Years to 21 Years
Enrollment
202 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2023
U.S. locations
3
States / cities
Baton Rouge, Louisiana • Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 7, 2023 · Synced Oct 27, 2026, 4:01 AM EDT
Completed Not applicable Interventional

Phase 2 Study of Adaptive Insulin Meal Supervisor (AIMS) in Adults With Type 1 Diabetes Mellitus

NCT01839370
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Closed Loop with Pramlintide
Device
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 19, 2014 · Synced Oct 27, 2026, 4:01 AM EDT
Completed Phase 1 Interventional

Proleukin and Rapamune in Type 1 Diabetes

NCT00525889
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
IL-2, Rapamycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
3
States / cities
New York, New York • Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Oct 27, 2026, 4:01 AM EDT
Completed Phase 3 Interventional Results available

Glucose Response of G-Pen (Glucagon Injection) in Pediatric T1D Patients

NCT03091673
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Glucagon
Drug
Lead sponsor
Xeris Pharmaceuticals
Industry
Eligibility
2 Years to 17 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
7
States / cities
Stanford, California • Aurora, Colorado • New Haven, Connecticut + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Oct 27, 2026, 4:01 AM EDT
Completed Not applicable Interventional Results available

Multi-center Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System and Control at Home

NCT02748018
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
670G and 770G Insulin Pump, Subject's Current Diabetes Therapy
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
2 Years to 80 Years
Enrollment
959 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
25
States / cities
La Jolla, California • Palo Alto, California • Sacramento, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 27, 2026, 4:01 AM EDT
Completed Phase 4 Interventional Results available

Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation

NCT00331162
View directory record Official record
Conditions
Graft Rejection
Interventions
Alemtuzumab, Anti-Thymocyte Globulin
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 65 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Oct 27, 2026, 4:01 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Identification of β Cell Dysfunction in Relatives of Individuals With Type 1 Diabetes Mellitus

NCT04362917
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
There is no intervention
Other
Lead sponsor
Indiana University
Other
Eligibility
12 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Oct 27, 2026, 4:01 AM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Ketone Monitoring Approaches for Diabetic Ketoacidosis Risk Mitigation in People With T1D on Adjunctive SGLT-2 Inhibitors

NCT07421518
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
SGLT-2 inhibitor (Sotagliflozin), Insulin withdrawal test (IWT)
Drug · Other
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
18 Years to 40 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 27, 2026, 4:01 AM EDT
Completed Phase 1 Interventional

Inpatient Evaluation of an Automated Closed-Loop Control-to-Range System

NCT01271023
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Control-to-Range Automated Insulin Management System
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
12 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
Santa Barbara, California • Stanford, California • Aurora, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2016 · Synced Oct 27, 2026, 4:01 AM EDT
Completed Not applicable Interventional Results available

Tailored Diabetes Self-Management Resources

NCT02024750
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Tailored Resources
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
8 Years to 16 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Madison, Wisconsin • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Oct 27, 2026, 4:01 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Children With Diabetes at Risk for Heart Disease.

NCT02275091
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Complications
Interventions
Not listed
Lead sponsor
Georgetown University
Other
Eligibility
12 Years to 21 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 5, 2019 · Synced Oct 27, 2026, 4:01 AM EDT
Enrolling by invitation Not applicable Interventional

T2D Intermittent Nonprescription Sensors for Informed Glucose Health Tracking

NCT07422831
View directory record Official record
Conditions
Type 2 Diabetes, Non Insulin Dependent Diabetes
Interventions
Periodic, over-the-counter continuous glucose monitoring
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 27, 2026, 4:01 AM EDT
Completed Phase 1 Interventional

Multiple Ascending Dose (MAD) Study of IMT-002 in HLA-DQ8-positive Type 1 Diabetes

NCT04625595
View directory record Official record
Conditions
Type1 Diabetes
Interventions
350mg BID (700mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule, 700mg BID (1400mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule, 1050mg QD (1050mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule, 1050mg BID (2100mg total daily) IMT-002, D-methyldopa, active formulation in capsule or Placebo, microcrystalline cellulose in capsule
Drug
Lead sponsor
Immunomolecular Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Chula Vista, California • Aurora, Colorado • Renton, Washington
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Oct 27, 2026, 4:01 AM EDT
Completed Not applicable Interventional

Adherence Intervention to Promote Optimal Use of Insulin Pumps in Adolescents With Type 1 Diabetes

NCT02333539
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Adherence behaviors and recommendations for improvement., Adherence behavior that needs improvement is targeted
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
10 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Oct 27, 2026, 4:01 AM EDT
Completed Not applicable Interventional

Effect of Protein Intake on Post Prandial Hyperglycemia in Children and Adolescents With Type1 Diabetes Mellitus

NCT04655131
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Hyperglycemia, Postprandial
Interventions
Whey protein isolate
Dietary Supplement
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
5 Years to 17 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Oct 27, 2026, 4:01 AM EDT
Completed Phase 2Phase 3 Interventional

TART - Troglitazone Atherosclerosis Regression Trial

NCT00116545
View directory record Official record
Conditions
Atherosclerosis, Diabetes Mellitus
Interventions
troglitazone
Drug
Lead sponsor
Parke-Davis
Industry
Eligibility
30 Years to 70 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2009 · Synced Oct 27, 2026, 4:01 AM EDT
Not yet recruiting Phase 2 Interventional

Precision T1D Platform - New Therapies for Cardio-Renal Complications

NCT07594145
View directory record Official record
Conditions
Type 1 Diabetes, T1D Heart Failure, Cardio-renal Vascular Function and Failure, Diabetic Chronic Kidney Disease
Interventions
Finerenone, Sotagliflozin
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Ann Arbor, Michigan • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 27, 2026, 4:01 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Disaster Preparedness Among Families Caring for Children With Diabetes

NCT00781313
View directory record Official record
Conditions
Diabetes
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2016 · Synced Oct 27, 2026, 4:01 AM EDT
Recruiting Phase 2 Interventional

Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment

NCT06411210
View directory record Official record
Conditions
Diabetes type1, Obesity
Interventions
Semaglutide Pen Injector, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 30 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 27, 2026, 4:01 AM EDT
Completed Phase 4 Interventional

Teplizumab in Pediatric Stage 2 Type 1 Diabetes

NCT05757713
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
teplizumab
Biological
Lead sponsor
Sanofi
Industry
Eligibility
0 Years to 7 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
10
States / cities
San Francisco, California • Aurora, Colorado • New Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 27, 2026, 4:01 AM EDT
Completed Not applicable Interventional Results available

Patient and Provider Glucose Reporting Preferences Ambulatory Glucose Profile (AGP)

NCT02074384
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Continuous Glucose Monitor, Self Monitoring Blood Glucose, Clinician
Device · Other
Lead sponsor
HealthPartners Institute
Other
Eligibility
7 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
New Haven, Connecticut • Tallahassee, Florida • Detroit, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2016 · Synced Oct 27, 2026, 4:01 AM EDT